![](https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/63c809b0acaf27b0a4de4c33_resources-hero_cell1.webp)
![](https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/63c809af6100c642491b1144_resources-hero_cell2.webp)
![](https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/63c809b0c9a071f3e1315c44_resources-hero_cell3.webp)
![](https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/63c809aff7e7c55068ea25b5_resources-hero_cell4.webp)
![](https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/63c809b0c077d95e001f56d8_resources-hero_cell5.webp)
![](https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/63c809b0a95ec247802ff9ad_resources-hero_cell6.webp)
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Jun 1, 2013
The Source Summer 2013
Magazine of the plasma protein therapeutics industry - Summer 2013
All
The Source magazine
![The Source Summer 2013](https://cdn.prod.website-files.com/6397a0a8e779b653e7149a60/647dc2fb6c6c83d632d8a35e_Summer2013.webp)
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/644fcd4ac13b6542eafac466_Source%20Summer%202013.pdf
Jun 1, 2013
The Source Summer 2013
Magazine of the plasma protein therapeutics industry - Summer 2013
All
The Source magazine
![The Source Summer 2013](https://cdn.prod.website-files.com/6397a0a8e779b653e7149a60/647dc2fb6c6c83d632d8a35e_Summer2013.webp)
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/644fcd4ac13b6542eafac466_Source%20Summer%202013.pdf
Mar 1, 2013
The Source Spring 2013
Magazine of the plasma protein therapeutics industry - Spring 2013
All
The Source magazine
![The Source Spring 2013](https://cdn.prod.website-files.com/6397a0a8e779b653e7149a60/63f79aa3816b0ad7676aedf4_Spring2013.png)
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/644fcd4da0a3e331ad336296_Source_Spring%202013.pdf
Mar 1, 2013
The Source Spring 2013
Magazine of the plasma protein therapeutics industry - Spring 2013
All
The Source magazine
![The Source Spring 2013](https://cdn.prod.website-files.com/6397a0a8e779b653e7149a60/63f79aa3816b0ad7676aedf4_Spring2013.png)
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/644fcd4da0a3e331ad336296_Source_Spring%202013.pdf
Dec 1, 2012
The Source Winter 2012
Magazine of the plasma protein therapeutics industry - Winter 2012
All
The Source magazine
![The Source Winter 2012](https://cdn.prod.website-files.com/6397a0a8e779b653e7149a60/647dbe060e044a9ddaccf25c_Winter2012.webp)
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/644fcd4d21fa0823b59bb26e_Source_Winter%202012.pdf
Dec 1, 2012
The Source Winter 2012
Magazine of the plasma protein therapeutics industry - Winter 2012
All
The Source magazine
![The Source Winter 2012](https://cdn.prod.website-files.com/6397a0a8e779b653e7149a60/647dbe060e044a9ddaccf25c_Winter2012.webp)
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/644fcd4d21fa0823b59bb26e_Source_Winter%202012.pdf
Nov 29, 2012
Citrate Anticoagulant and Apheresis Perspective of Plasma Protein Therapeutics Industry
Following the meeting of the Blood Commission on November 16, 2011, where the Amrein et al. study of plateletpheresis donors that reported bone mineral density (BMD) losses at one of three skeletal sites was associated with donating platelets1 was discussed, the Plasma Protein Therapeutics Association (PPTA) was asked to respond to the suggestion that Source Plasma donors, with their high-frequency, high-volume donations, were at risk of BMD loss. The industry has evaluated the Amrein et al. study,
conducted extensive literature surveys to see if similar findings had been published, and assessed risk to plasma donors looking at the comparison of the exposures to citrate that plasma and platelet donors would receive during the apheresis collection process. The result of this analysis is presented in this paper to address the Blood Commission’s concerns.
All
Publication
https://plasmaprotein.sharepoint.com/:b:/s/RL/EbaJfhE_GLhAjcPW3W4hvJQBf4wfvMGx51kHU6BNcRE3ug?e=sxrh2D
Nov 29, 2012
Citrate Anticoagulant and Apheresis Perspective of Plasma Protein Therapeutics Industry
Following the meeting of the Blood Commission on November 16, 2011, where the Amrein et al. study of plateletpheresis donors that reported bone mineral density (BMD) losses at one of three skeletal sites was associated with donating platelets1 was discussed, the Plasma Protein Therapeutics Association (PPTA) was asked to respond to the suggestion that Source Plasma donors, with their high-frequency, high-volume donations, were at risk of BMD loss. The industry has evaluated the Amrein et al. study,
conducted extensive literature surveys to see if similar findings had been published, and assessed risk to plasma donors looking at the comparison of the exposures to citrate that plasma and platelet donors would receive during the apheresis collection process. The result of this analysis is presented in this paper to address the Blood Commission’s concerns.
All
Publication
https://plasmaprotein.sharepoint.com/:b:/s/RL/EbaJfhE_GLhAjcPW3W4hvJQBf4wfvMGx51kHU6BNcRE3ug?e=sxrh2D
No results found